/ /


Novel treatment options for IOP involve range of independent factorsWhen exploring novel treatment options for the management of IOP, clinicians should consider a number of independent factors ranging from beneficial behaviors to body position.
Managing residual astigmatism after toric IOL surgeryResidual astigmatism is not uncommon after toric IOL implantation. Depending on its cause and magnitude, lens reorientation may be a good solution.
Study finds advantages using trifocal IOL to correct presbyopiaA 4-year study following trifocal IOL implantation (AT LISA tri 839MP, Carl Zeiss Meditec) found that the lens provided good distance, near, and intermediate visual acuity. The lens also improved patient quality of vision with better diffraction and less reduction in contrast sensitivity.
Exploring wider role for premium IOL implantation in glaucoma patientsWhen it comes to recommending a premium IOL, a patient’s glaucoma is only one factor to consider. Just like any other patient planning cataract surgery, visual needs and preferences for/against glasses are also important factors.
Reactivating cones possibility in addressing RPGlucose entrapment in the retinal pigment epithelium is responsible for central vision loss in retinitis pigmentosa. Injecting wild-type rods into the eye to restore glucose transportation or injecting glucose into the subretinal space can facilitate cone regeneration.
How to achieve a calm, stress-free ORAchieving the best visual outcomes in challenging cases is a high priority in surgical retina. However, meeting that goal involves a high level of creativity, especially in complex cases associated with other ocular comorbidities.
Intraoperative OCT faces prime time, but added technology neededIntraoperative optical coherence tomography (OCT) is becoming widely available, and its adoption is increasing, but improvements in the technology are needed to maximize its readiness for prime time, according to Justis P. Ehlers, MD.
Why content is still king
Why content is still kingOne thing has remained constant since the inception of Google: the importance of unique and compelling content. So, the answer seems to be just keep adding content to your website—right? Unfortunately, no.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.


View Results